Hasbrouck Heights-based Nymox Pharmaceutical Corp. announced it has enrolled the first patient in a company study of the safety and efficacy of NX-1207 reinjection for the treatment of prostate enlargement, according to a release.
The new study will enroll 100 to 200 patients who had previously participated in an NX-1207 study. The use of NX-1207 for the treatment of moderate to severe prostate enlargement is being evaluated in five Phase 3 trials. NX-1207 is injected by a urologist under ultrasound guidance directly into the area of the prostate to be treated in an in-clinic procedure that takes only a few minutes and does not require catheterization, anesthetics or sedation.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy